Arbutus Biopharma (ABUS) Receivables (2010 - 2026)

Arbutus Biopharma has disclosed Receivables across 17 years of filings, most recently posting $178.7 million for Q1 2026.

• Receivables for Q1 2026 came in at $178.7 million, up 15021.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $178.7 million (up 15021.91% YoY), and the FY2025 annual result was $1.4 million, down 39.93% from the prior year.
• Receivables came in at $178.7 million for Q1 2026 at Arbutus Biopharma, up from $1.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $178.7 million in Q1 2026 to a low of $905000.0 in Q3 2025.
• The 5-year median for Receivables is $1.8 million (2023), against an average of $12.2 million.
• Across the five-year window, Receivables slumped 44.74% in 2025 and soared 15021.91% in 2026, its largest moves.
• Arbutus Biopharma's Receivables stood at $1.4 million in 2022, then soared by 31.36% to $1.8 million in 2023, then surged by 35.64% to $2.4 million in 2024, then tumbled by 39.93% to $1.4 million in 2025, then jumped by 12252.52% to $178.7 million in 2026.
• The last three Receivables figures came in at $178.7 million (Q1 2026), $1.4 million (Q4 2025), and $905000.0 (Q3 2025), per Business Quant data.